生物活性
CUDC-101是一种抑制多种靶标的新型化合物,旨在抑制HDAC,EGFR和Her2。
Targets
Target | Value |
EGFR | IC50: 2.4nM |
HDAC | IC50: 4.4nM |
HDAC1 | IC50: 4.5nM |
HDAC6 | IC50: 5.1nM |
HDAC3 | IC50: 9.1nM |
HDAC5 | IC50: 11.4nM |
HDAC2 | IC50: 12.6nM |
HDAC4 | IC50: 13.2nM |
HER2 | IC50: 15.7nM |
HDAC10 | IC50: 26.1nM |
HDAC9 | IC50: 67.2nM |
HDAC8 | IC50: 79.8nM |
HDAC7 | IC50: 373nM |
化学数据
目录号 | A10246 |
作用机制 | Inhibitor (抑制剂) |
M. Wt | 434.5 |
Formula | C24H26N4O4 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for36 months. In solution, store at -20ºC and use within3 monthsto prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
CAS No. | 1012054-59-9 |
Synonyms | CUDC101 |
SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
溶解度
In vitro (25°C) | DMSO | 20 mg/mL (46.03 mM) |
Water | Insoluble |
Ethanol | Insoluble |
In vivo | 15% Captisol | 28 mg/mL |
*<1 mg/ml means slightly soluble or insoluble. *Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
储备液配制
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
0.1 mM | 23.01 mL | 115.07 mL | 230.15 mL |
0.5 mM | 4.6 mL | 23.01 mL | 46.03 mL |
1 mM | 2.3 mL | 11.51 mL | 23.01 mL |
5 mM | 0.46 mL | 2.3 mL | 4.6 mL |
*The above data is based on the productmolecular weight 434.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.